NO20053335L - 2-aminokarbonyl-kinolinforbindelser som blodplateadenosindifosfatreseptorer. - Google Patents
2-aminokarbonyl-kinolinforbindelser som blodplateadenosindifosfatreseptorer.Info
- Publication number
- NO20053335L NO20053335L NO20053335A NO20053335A NO20053335L NO 20053335 L NO20053335 L NO 20053335L NO 20053335 A NO20053335 A NO 20053335A NO 20053335 A NO20053335 A NO 20053335A NO 20053335 L NO20053335 L NO 20053335L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- aminocarbonylquinoline
- adenosine diphosphate
- platelet adenosine
- receptors
- Prior art date
Links
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 title abstract 2
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43279202P | 2002-12-11 | 2002-12-11 | |
| PCT/US2003/039079 WO2004052366A1 (en) | 2002-12-11 | 2003-12-09 | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053335D0 NO20053335D0 (no) | 2005-07-08 |
| NO20053335L true NO20053335L (no) | 2005-09-07 |
Family
ID=32507994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053335A NO20053335L (no) | 2002-12-11 | 2005-07-08 | 2-aminokarbonyl-kinolinforbindelser som blodplateadenosindifosfatreseptorer. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7056923B2 (de) |
| EP (1) | EP1578423B1 (de) |
| JP (1) | JP4662777B2 (de) |
| KR (1) | KR20050085580A (de) |
| CN (1) | CN1747732A (de) |
| AP (1) | AP2005003363A0 (de) |
| AT (1) | ATE477800T1 (de) |
| AU (1) | AU2003297763A1 (de) |
| BR (1) | BR0317222A (de) |
| CA (1) | CA2507657C (de) |
| DE (1) | DE60333866D1 (de) |
| EA (1) | EA200500899A1 (de) |
| EC (1) | ECSP055912A (de) |
| ES (1) | ES2348942T3 (de) |
| MX (1) | MXPA05006302A (de) |
| NO (1) | NO20053335L (de) |
| NZ (1) | NZ540872A (de) |
| OA (1) | OA12970A (de) |
| PL (1) | PL377053A1 (de) |
| RS (1) | RS20050450A (de) |
| UA (1) | UA83648C2 (de) |
| WO (1) | WO2004052366A1 (de) |
| ZA (1) | ZA200505492B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| DE602004027409D1 (de) * | 2003-10-21 | 2010-07-08 | Inspire Pharmaceuticals Inc | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
| TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CA2619706A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity quinoline-based kinase ligands |
| DE102006020385A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
| CL2007002920A1 (es) * | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) * | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| CA2684644A1 (en) * | 2007-04-23 | 2008-10-30 | Sanofi-Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| MX2009013431A (es) | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
| RU2483072C2 (ru) | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| MX2011010200A (es) * | 2009-04-08 | 2011-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp). |
| JP5536876B2 (ja) | 2009-04-22 | 2014-07-02 | アクテリオン ファーマシューティカルズ リミテッド | チアゾール誘導体及びp2y12受容体拮抗剤としてのそれらの使用 |
| CN102304108B (zh) * | 2011-06-28 | 2013-11-06 | 中国药科大学 | 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途 |
| CN104151235B (zh) * | 2014-08-07 | 2016-01-20 | 南阳师范学院 | 一种喹啉衍生物制备方法 |
| CN109715639B (zh) | 2016-09-22 | 2022-04-19 | 爱杜西亚药品有限公司 | 结晶形式 |
| SG11201908128YA (en) | 2017-03-15 | 2019-10-30 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
| CN112920181A (zh) * | 2021-01-29 | 2021-06-08 | 中国医科大学 | N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US60474A (en) * | 1866-12-18 | Pbtee chick | ||
| GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
| US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| KR920703558A (ko) | 1990-11-15 | 1992-12-18 | 원본미기재 | 메타-치환 페닐알라닌 유도체 |
| WO1994018185A1 (de) * | 1993-02-10 | 1994-08-18 | Pentapharm Ag | Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren |
| KR0173034B1 (ko) * | 1995-04-28 | 1999-03-30 | 성재갑 | 선택적 트롬빈 억제제 |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
-
2003
- 2003-12-09 CN CNA2003801096637A patent/CN1747732A/zh active Pending
- 2003-12-09 US US10/731,815 patent/US7056923B2/en not_active Expired - Fee Related
- 2003-12-09 AP AP2005003363A patent/AP2005003363A0/xx unknown
- 2003-12-09 CA CA2507657A patent/CA2507657C/en not_active Expired - Fee Related
- 2003-12-09 JP JP2004558607A patent/JP4662777B2/ja not_active Expired - Fee Related
- 2003-12-09 RS YUP-2005/0450A patent/RS20050450A/sr unknown
- 2003-12-09 DE DE60333866T patent/DE60333866D1/de not_active Expired - Lifetime
- 2003-12-09 BR BR0317222-8A patent/BR0317222A/pt not_active IP Right Cessation
- 2003-12-09 UA UAA200506729A patent/UA83648C2/ru unknown
- 2003-12-09 EA EA200500899A patent/EA200500899A1/ru unknown
- 2003-12-09 KR KR1020057010688A patent/KR20050085580A/ko not_active Withdrawn
- 2003-12-09 EP EP03796831A patent/EP1578423B1/de not_active Expired - Lifetime
- 2003-12-09 MX MXPA05006302A patent/MXPA05006302A/es active IP Right Grant
- 2003-12-09 ES ES03796831T patent/ES2348942T3/es not_active Expired - Lifetime
- 2003-12-09 OA OA1200500175A patent/OA12970A/en unknown
- 2003-12-09 PL PL377053A patent/PL377053A1/pl not_active Application Discontinuation
- 2003-12-09 NZ NZ540872A patent/NZ540872A/en unknown
- 2003-12-09 AT AT03796831T patent/ATE477800T1/de not_active IP Right Cessation
- 2003-12-09 AU AU2003297763A patent/AU2003297763A1/en not_active Abandoned
- 2003-12-09 WO PCT/US2003/039079 patent/WO2004052366A1/en not_active Ceased
-
2005
- 2005-07-08 NO NO20053335A patent/NO20053335L/no not_active Application Discontinuation
- 2005-07-11 EC EC2005005912A patent/ECSP055912A/es unknown
-
2006
- 2006-01-12 US US11/331,621 patent/US7084142B2/en not_active Expired - Fee Related
- 2006-01-17 ZA ZA200505492A patent/ZA200505492B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7084142B2 (en) | 2006-08-01 |
| NZ540872A (en) | 2007-08-31 |
| WO2004052366A9 (en) | 2005-06-23 |
| US20040138229A1 (en) | 2004-07-15 |
| CA2507657A1 (en) | 2004-06-24 |
| DE60333866D1 (de) | 2010-09-30 |
| AU2003297763A1 (en) | 2004-06-30 |
| OA12970A (en) | 2006-10-13 |
| JP2006511519A (ja) | 2006-04-06 |
| CN1747732A (zh) | 2006-03-15 |
| WO2004052366A1 (en) | 2004-06-24 |
| ECSP055912A (es) | 2005-11-22 |
| EP1578423A1 (de) | 2005-09-28 |
| CA2507657C (en) | 2011-05-31 |
| NO20053335D0 (no) | 2005-07-08 |
| JP4662777B2 (ja) | 2011-03-30 |
| ATE477800T1 (de) | 2010-09-15 |
| UA83648C2 (ru) | 2008-08-11 |
| EP1578423B1 (de) | 2010-08-18 |
| AP2005003363A0 (en) | 2005-09-30 |
| ZA200505492B (en) | 2006-03-29 |
| US20060122188A1 (en) | 2006-06-08 |
| KR20050085580A (ko) | 2005-08-29 |
| PL377053A1 (pl) | 2006-01-23 |
| EA200500899A1 (ru) | 2006-02-24 |
| ES2348942T3 (es) | 2010-12-17 |
| BR0317222A (pt) | 2005-11-01 |
| RS20050450A (sr) | 2007-08-03 |
| MXPA05006302A (es) | 2005-08-29 |
| US7056923B2 (en) | 2006-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
| NO20066055L (no) | Pyridinderivater | |
| NO20054080L (no) | Aminoheteroarylforbindelser som roteinkinaseinhibitorer | |
| WO2002098856A3 (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
| DE60204452D1 (de) | Pyrazolo[1,5]pyridinderivate | |
| NO20050828L (no) | lndol-3-svovelderivater | |
| NO20022095L (no) | Heterocyklisk substituerte pyrazoloner | |
| NO20006323L (no) | Glykopeptid-derivater og farmasöytiske sammensetninger som inneholder disse | |
| SE0200920D0 (sv) | Novel compounds | |
| NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
| JO2353B1 (en) | New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use | |
| NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| ATE433981T1 (de) | Heterocyclische verbindungen | |
| DK1268471T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
| NO20051695L (no) | Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer | |
| NO20054329L (no) | Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike | |
| NO20022202L (no) | 5-aryl-1H-1,2,4-triazol forbindelser som inhibitorer av cyclooksygenase-2 og farmasöytiske preparater inneholdende disse | |
| DK1517890T3 (da) | Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
| SG140591A1 (en) | Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| UA83648C2 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| NO20063062L (no) | Imidazolderivater, fremgangsmate for fremstilling og anvendelse av disse | |
| IL163625A0 (en) | Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same | |
| NO20052794L (no) | Antibakterielle indolonoksazolidinoner intermediater for fremstilling av disse og farmasoytiske prepareter inneholdende disse | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |